Top Markets
Coin of the day
Alpine Immune Sciences, Inc. Alpine Immune Sciences, Inc.

Alpine Immune Sciences, Inc.

ALPN
Kedudukan dalam Saham #6581
Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company... Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company focused on discovering and advancing protein-based immunotherapies. Their therapeutic endeavors address a range of conditions, including various cancers, autoimmune and inflammatory disorders, among others. The company's pipeline features ALPN-101, an ICOS/CD28 antagonist program being developed for autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor aimed at treating cancer; and ALPN-303, a dual B cell cytokine antagonist for B cell-mediated inflammatory and autoimmune conditions. Alpine Immune Sciences has established strategic collaborations, including an agreement with AbbVie Ireland Unlimited Company for the development of ALPN-101, and a partnership with Adaptimmune Therapeutics plc to create next-generation SPEAR T cell products. The company was founded in 2007 and operates from its headquarters in Seattle, Washington.
Harga Saham
$64.97
Disegerakkan terakhir: 2024-05-20
Modal Pasaran
$1.97B
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
0.00%
Negara
US
Perdagangan Alpine Immune Sciences, Inc. (ALPN)

Kategori

Hasil untuk Alpine Immune Sciences, Inc. (ALPN)
Hasil pada Mar 2024 TTM: $56.52M
Menurut laporan kewangan terkini daripada Alpine Immune Sciences, Inc., hasil semasa syarikat (TTM) ialah $56.52M. Pada tahun 2022, syarikat memperoleh hasil sebanyak $30.06M peningkatan berbanding hasil pada tahun 2021 iaitu $23.44M. Hasil ialah jumlah pendapatan keseluruhan yang dijana oleh syarikat daripada jualan barangan atau perkhidmatan. Tidak seperti keuntungan, tiada perbelanjaan ditolak.
Sejarah hasil bagi Alpine Immune Sciences, Inc. dari 2012 hingga 2026
Hasil pada akhir setiap tahun
Tahun Hasil Ubah
2026 (TTM) $56.52M -4.00%
2023 $58.88M 95.84%
2022 $30.06M 28.24%
2021 $23.44M 151.13%
2020 $9.34M 436.49%
2019 $1.74M 146.81%
2018 $705.00K -59.27%
2017 $1.73M -41.32%
2016 $2.95M 499.59%
2015 $492.00K 0.00%
2014 0.00 0.00%
2013 0.00 0.00%
2012 0.00 0.00%
Hasil untuk syarikat atau pesaing serupa
Syarikat Hasil Perbezaan Hasil Negara
$12.62B 22,235.59%
US
$6.02B 10,553.19%
NL
$15.74B 27,755.71%
AU
$2.23B 3,841.90%
US
- -
CH